TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3301606

Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg three times daily, orally, before meals
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 18
Study: 2806497

Group type: EXPERIMENTAL
Intervention: Inhalation of cold dry air for 2 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhalation of cold dry air for 3 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhalation of cold dry air for 4 minutes
Number of subjects: 12
Study: 30686542

Group type: EXPERIMENTAL
Intervention: Citrate Dialysis Fluid (CDF) with 1mmol/L of citrate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acetate Dialysis Fluid (ADF) with 3mmol/L of acetate
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Citrate Dialysis Fluid (CDF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acetate Dialysis Fluid (ADF)
Number of subjects: 56
Study: 28800398

Group type: EXPERIMENTAL
Intervention: PROG (lifestyle modification program with targeted nutraceutical supplementation)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PROG
Number of subjects: 44

Group type: COMPARATOR
Intervention: DIET (lifestyle modification program without nutraceutical supplementation)
Number of subjects: 44
Study: 25434500

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of tramadol intramuscularly (group T; n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 g of paracetamol intravenously (group P; n = 30)
Number of subjects: 60
Study: 24296481

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation (8 weeks, 3 to 5 sessions per week, minimum of 1 supervised session)
Number of subjects: 128
Study: 21502222

Group type: EXPERIMENTAL
Intervention: Responsive stimulation and feeding intervention (6 sessions with peer educators)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Responsive stimulation and feeding intervention with micronutrient fortification (6 sessions + 6 months of fortified food powder)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Regular information-based parenting program (12 informational sessions on health and nutrition)
Number of subjects: 302
Study: 19374960

Group type: EXPERIMENTAL
Intervention: Short waiting time (<=3 months)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Non-fixed waiting time (>3 months)
Number of subjects: 309
Study: 16740859

Group type: EXPERIMENTAL
Intervention: Physician Asthma Care Education program
Number of subjects: 870
Study: 16249508

Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide (500 ppm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (synthetic air without CO)
Number of subjects: 15
Study: 11565320

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 0
Study: 9627524

Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg
Number of subjects: 89
Study: 7933821

Group type: EXPERIMENTAL
Intervention: Human atrial natriuretic peptide (ANP) at 0.20 micrograms/kg/min i.v. for 24 hours or 0.08 micrograms/kg/min i.a. for 8 hours, with furosemide or mannitol or no diuretic.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (Group II) treated with diuretics or no diuretic, without ANP.
Number of subjects: 53
Study: 3065976

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31140342

Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics in patients with substance use
Number of subjects: 226

Group type: COMPARATOR
Intervention: Second generation antipsychotics in patients without substance use
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 226
Study: 29048352

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) in fermented milk (6.5 × 10⁸ cfu) daily for 8 weeks
Number of subjects: 60
Study: 26160525

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg t.i.d. for 1 month
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 23307258

Group type: EXPERIMENTAL
Intervention: FLOT regimen (oxaliplatin 85 mg/m², docetaxel 50 mg/m², leucovorin 200 mg/m², 5-FU 1200 mg/m²) administered biweekly
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: FLOT regimen
Number of subjects: 50
Study: 21217084

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m(2) weekly × nine cycles
Number of subjects: 285

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m(2) every 21 days × six cycles (Control)
Number of subjects: 285
Study: 19080741

Group type: EXPERIMENTAL
Intervention: Combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors coupled with LH-RH agonists
Number of subjects: 0
Study: 17160909

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (rosiglitazone, pioglitazone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 0
Study: 14533658

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 88 microg and salmeterol 42 microg (FSC) in a CFC-free MDI
Number of subjects: 283

Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg (FP) in a CFC-containing MDI
Number of subjects: 283

Group type: COMPARATOR
Intervention: Salmeterol 42 microg in a CFC-containing MDI
Number of subjects: 283
Study: 11302273

Group type: EXPERIMENTAL
Intervention: Preventive intervention group
Number of subjects: 66

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 66
Study: 9399371

Group type: EXPERIMENTAL
Intervention: Food deprivation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Incentive motivation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no food deprivation)
Number of subjects: 82
Study: 8309607

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg/4 hours i.v. during the first 24 hours, 2 mg/6 hours during the following 24 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Octreotide (50 micrograms i.v. followed by 25 micrograms/hour infusion)
Number of subjects: 30
Study: 3103764

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Bladder drill
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Propantheline
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 211
Study: 30061194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study: 27422625

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 25409020

Group type: EXPERIMENTAL
Intervention: Pistachio supplementation (3 oz./d for 2 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No pistachio supplementation (control)
Number of subjects: 19
Study: 22959217

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 120 mg twice per day
Number of subjects: 2854

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2854

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761)
Number of subjects: 2854
Study: 20534062

Group type: EXPERIMENTAL
Intervention: Honey supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional nutritional rehabilitation therapy
Number of subjects: 30
Study: 18198649

Group type: EXPERIMENTAL
Intervention: Retention enema with combination of Chinese and Western drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western drugs alone
Number of subjects: 0
Study: 15613587

Group type: EXPERIMENTAL
Intervention: Applying the sensor to the infant before connecting to the oximeter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control method not specified
Number of subjects: 0
Study: 11881888

Group type: EXPERIMENTAL
Intervention: Ibuprofen (5 mg kg(‐1))
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Rofecoxib (0.625 mg kg(‐1))
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 10221802

Group type: EXPERIMENTAL
Intervention: Full chart visual acuity test
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single line visual acuity test
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single optotype visual acuity test
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (ophthalmologically normal children)
Number of subjects: 75
Study: 7894298

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2505698

Group type: EXPERIMENTAL
Intervention: Fibronectin (Fn)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Human serum albumin (HSA)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 85
Study: 335196

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 60
Study: 31969369

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Number of subjects: 160

Group type: COMPARATOR
Intervention: Nitrate-deplete beetroot juice (placebo)
Number of subjects: 160
Study: 31784567

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV) testing
Number of subjects: 2385

Group type: EXPERIMENTAL
Intervention: Statistical simulation for expected incidence of ALRI
Number of subjects: 2385

Group type: EXPERIMENTAL
Intervention: Comparison of ALRI cases due to RSV vs PIV or IV
Number of subjects: 2385
Study: 27671119

Group type: EXPERIMENTAL
Intervention: HIV/AIDS education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV/AIDS education + home‐based VCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV/AIDS education + CCT for facility‐based VCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: home‐based VCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCT for facility‐based VCT
Number of subjects: 0
Study: 27233921

Group type: EXPERIMENTAL
Intervention: Calanus oil (2 g daily for one year)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 64
Study: 24702797

Group type: EXPERIMENTAL
Intervention: Peer adherence support (PAS) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer adherence support (PAS) intervention with nutritional support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 22510791

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1400 IU weekly from birth to 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 0
Study: 20538398

Group type: EXPERIMENTAL
Intervention: Polyvinylpyrrolidone sodium hyaluronate gel (Aloclair) 3 times daily for 1 week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate gel 3 times daily for 1 week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 18525382

Group type: EXPERIMENTAL
Intervention: Exercise capacity over 230 W
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Exercise workload (for 20 W increment)
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: European SCORE (for 1% increment)
Number of subjects: 1639
Study: 16198768

Group type: EXPERIMENTAL
Intervention: 25-month interferon alfa 2b treatment (10 MU 5 days a week for 4 weeks, then 10 MU three times a week for 1 year)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: 13-month interferon alfa 2b treatment (10 MU 5 days a week for 4 weeks, then 5 MU three times a week for 2 years)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 1388
Study: 12357302

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (80 mg/m²) administered after fasting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral vinorelbine (80 mg/m²) administered after ingestion of a standard continental breakfast
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (80 mg/m²) in both feeding conditions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (80 mg/m²)
Number of subjects: 18
Study: 10550358

Group type: EXPERIMENTAL
Intervention: Dithranol + Tazarotene (combined therapy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dithranol (monotherapy)
Number of subjects: 50
Study: 7750526

Group type: EXPERIMENTAL
Intervention: BCG, 81 mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: BCG, 27 mg
Number of subjects: 500
Study: 10147031

Group type: EXPERIMENTAL
Intervention: Patient education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 6712861

Group type: EXPERIMENTAL
Intervention: Propranolol (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (chronic treatment for 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (chronic treatment for 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 0
Study: 31309919

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) + n-3 fatty acids (2× 1000 mg/d from flaxseed oil)
Number of subjects: 61
Study: 29695280

Group type: EXPERIMENTAL
Intervention: Ekso™ gait training (EGT) (45-min/session, five times/week)
Number of subjects: 40
Study: 26600191

Group type: EXPERIMENTAL
Intervention: Esophageal stent (SX-ELLA Danis)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Balloon tamponade (Sengstaken-Blakemore tube)
Number of subjects: 28
Study: 24951467

Group type: EXPERIMENTAL
Intervention: CloB2A2 regimen (clofarabine 30 mg/m(2)/day for 4 days, busulfan 3.2 mg/kg/day for 2 days, antithymocyte globulin 2.5 mg/kg/day for 2 days)
Number of subjects: 30
Study: 24077218

Group type: EXPERIMENTAL
Intervention: Longitudinal SRMs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transverse SRMs
Number of subjects: 15

Group type: COMPARATOR
Intervention: No SRMs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transverse speed reduction markings (TSRMs)
Number of subjects: 15
Study: 22580729

Group type: EXPERIMENTAL
Intervention: Medium-chain saturated fatty acids (SFA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Medium-chain saturated fatty acids (SFA) and Monounsaturated fatty acids (MUFA)
Number of subjects: 34
Study: 19101220

Group type: EXPERIMENTAL
Intervention: Low-dose caldaret
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: High-dose caldaret
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 17894265

Group type: EXPERIMENTAL
Intervention: Robot training with MIT‐MANUS for shoulder and elbow, and novel distal wrist robot.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group of stroke survivors (40 participants).
Number of subjects: 200
Study: 15472771

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional analgesic measures (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 11533423

Group type: EXPERIMENTAL
Intervention: Patient held record
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (no patient held record)
Number of subjects: 501
Study: 9595866

Group type: EXPERIMENTAL
Intervention: Mental stress induction in migraine patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Mental stress induction in tension headache patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Mental stress induction in control group
Number of subjects: 23
Study: 7778569

Group type: EXPERIMENTAL
Intervention: Managed care health plans (capitated payment)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Fee-for-service (FFS) plans
Number of subjects: 387
Study: 2156887

Group type: EXPERIMENTAL
Intervention: Finasteride 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride 0.04 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride 0.12 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride 0.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 7410324

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TAD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other psychoactive drugs or placebo
Number of subjects: 0
Study: 31895769

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study: 31722623

Group type: EXPERIMENTAL
Intervention: RAND/PPMD Patient‐Centeredness Method (RPM)
Number of subjects: 122
Study: 28803386

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day (n=60)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Sexual intercourse at least three times a week (n=66)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard medical therapy alone (n=64)
Number of subjects: 190
Study: 25602299

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg a day for 2 weeks
Number of subjects: 4373
Study: 23603397

Group type: EXPERIMENTAL
Intervention: Neuropostural optimization (NPO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 31
Study: 21842454

Group type: EXPERIMENTAL
Intervention: Orthopedic shoes (intervention group)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No orthopedic treatment (control group)
Number of subjects: 220
Study: 20082930

Group type: EXPERIMENTAL
Intervention: Exercise (60 min, 3 times/week for 3 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (relatively inactive)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (after crossover)
Number of subjects: 44
Study: 17555465

Group type: EXPERIMENTAL
Intervention: Sirolimus (n = 30; dosed to maintain trough concentrations of 10‐25 ng ml(‐1) until week 8, and then 8‐15 ng ml(‐1) thereafter) in combination with daclizumab, oral MMF and corticosteroids
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ciclosporin (CsA) (n = 15; administered as per centre practice) in combination with daclizumab, oral MMF and corticosteroids
Number of subjects: 45
Study: 15104606

Group type: EXPERIMENTAL
Intervention: 100 microg of oral misoprostol
Number of subjects: 200

Group type: COMPARATOR
Intervention: 3 mg prostaglandin E2 vaginal tablets
Number of subjects: 200
Study: 11681540

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Right hemisphere stimulation (rTMS)
Number of subjects: 81

Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 81
Study: 9010987

Group type: EXPERIMENTAL
Intervention: Granisetron 5 micrograms/kg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms/kg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Granisetron (combined doses)
Number of subjects: 353
Study: 7944533

Group type: EXPERIMENTAL
Intervention: Continuous oral flucloxacillin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Antibiotics when clinically indicated
Number of subjects: 42
Study: 2178851

Group type: EXPERIMENTAL
Intervention: Desipramine (mean dose, 167 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 289417

Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole (Flagyl) 200 mg every 8 hours for 3 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 30805958

Group type: EXPERIMENTAL
Intervention: 12-14 months multi-strategic intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 70
Study: 27887885

Group type: EXPERIMENTAL
Intervention: Exposure to a 'watching-eyes image' on a blood-donation flyer
Number of subjects: 454

Group type: COMPARATOR
Intervention: Neutral picture on a blood-donation flyer (control condition)
Number of subjects: 454
Study: 25851076

Group type: EXPERIMENTAL
Intervention: Automatic HbA1C orders for patients receiving chronic glucocorticoid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 38
Study: 23808185

Group type: EXPERIMENTAL
Intervention: Combined therapy of mexidol 100 mg and picamilon 150 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined therapy of mexidol 300 mg and picamilon 150 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Picamilon 150 mg
Number of subjects: 94
Study: 21865944

Group type: EXPERIMENTAL
Intervention: Aggressive glycemic control (90‐120 mg/dL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Moderate glycemic control (120‐180 mg/dL)
Number of subjects: 82
Study: 19442782

Group type: EXPERIMENTAL
Intervention: 600 mcg oral misoprostol
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 300
Study: 17141985

Group type: EXPERIMENTAL
Intervention: New amoxicillin/clavulanate therapeutic system (1500 mg amoxicillin and 125 mg clavulanic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular immediate release amoxicillin/clavulanate formulation
Number of subjects: 0